about
Antibiotic strategies in the era of multidrug resistanceRidinilazole: a novel therapy for Clostridium difficile infectionThe Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in EnglandRapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective studyShort-term genome stability of serial Clostridium difficile ribotype 027 isolates in an experimental gut model and recurrent human diseaseA pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillanceEfficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.Molecular epidemiology of endemic Clostridium difficile infection and the significance of subtypes of the United Kingdom epidemic strain (PCR ribotype 1)International Clostridium difficile animal strain collection and large diversity of animal associated strainsClinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing.Diverse temperate bacteriophage carriage in Clostridium difficile 027 strains.Evolutionary history of the Clostridium difficile pathogenicity locusClostridium difficile: changing epidemiology and new treatment options.Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.Parameters for the mathematical modelling of Clostridium difficile acquisition and transmission: a systematic reviewDevelopment and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota.Efficacy of linezolid versus comparator therapies in Gram-positive infections.Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis.Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotypeHealth-care-associated infection: morbidity, mortality and costs.Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes.Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.Models for the study of Clostridium difficile infection.Predictors of first recurrence of Clostridium difficile infection: implications for initial managementAntibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harmAntibiotic prescribing as a risk factor for MRSA.Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin ProductionUpdate on linezolid: the first oxazolidinone antibiotic.Tigecycline and the need for a new broad-spectrum antibiotic class.Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test studyAssessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy studyRecombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing.Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection.Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infectionDiverse sources of C. difficile infection identified on whole-genome sequencing.Whole genome sequencing and de novo assembly identifies Sydney-like variant noroviruses and recombinants during the winter 2012/2013 outbreak in England
P50
Q26744091-6F093F3D-DAF5-4E1C-9605-9003860F62E5Q26747248-193FFE67-E05A-4E3A-AF55-EC00A21D3E50Q26783950-9318B0F7-54F9-4829-827B-1C80DCDBB92CQ28603336-7D9F0C46-F96F-43D3-A223-F0056B30BA7AQ28703592-F178C89E-1A70-43BE-B85F-BDE834CDA76BQ28728239-C7DAC403-2E18-4352-B143-634A4401B8C3Q33831557-90DCD879-5DB6-4D2B-AF37-5EB857B67EB8Q33856234-82B14BB6-DB9E-42B2-86D5-C0F1193A36D8Q33909227-35294E8C-C12C-483D-BA99-44D72766E3B2Q34105840-D4500364-46E7-42C5-B028-8C17D5C7C8BBQ34162226-EAE61F16-A0A2-4CE6-9CEB-29BC1546EC5AQ34279867-49503FFC-C4FE-4549-A8C8-97AE35C3D4AAQ34391822-34631ADF-109B-46EB-9AB7-5175CA2085A2Q34645735-1AB8E288-B47C-4A66-ADCF-E8B548D473F9Q34900607-558B1DBD-CA18-43AC-933D-56140DE482B1Q35078355-48CA18CD-74B6-41B9-8393-440D027993BEQ35091728-5CF15298-855E-4867-BFD0-AC179F83E27FQ35120951-B22B3C97-8C0A-481B-A3E3-5A676F8C2777Q35134579-59A8F56A-ECED-48AF-9DB7-A3B741DDB25EQ35161614-59A12DD9-4D3D-4A3B-B16A-25F30802A782Q35598962-C6684B15-64B7-4D37-B2EB-F09E9AD4A73FQ35680956-5C0300F3-2FB0-4F2A-ACC5-A4367FBAD23AQ35784394-A29374F1-BCE3-4DD6-9728-1AD250AA12EEQ35786897-F61FB629-7AAC-4AB3-831A-4DAD98A05813Q35891356-07B826E5-71F9-426C-9D84-C53AE2E95689Q35998772-8127F2E8-A8BC-4A26-B504-FB3F41E2DC67Q36019356-4A28E3A5-A465-42C4-93B8-B835AE7A7C94Q36071508-76BB99FC-F6DE-4414-BB27-BED76DBCED0EQ36078316-B672368F-CE9B-42CB-9E08-46D8642A7E3BQ36080672-C1F2AAA0-AEF0-4A8D-A315-50C149E496DFQ36111393-D6BBBD0E-D20A-44BE-AF6B-D58B1FF80111Q36283744-87484290-6A1C-4A4A-B759-60A4E3799A7EQ36410409-14B72AA3-D2B9-4DF2-A67D-FF8E5F51C417Q36462147-EE6094B7-66A4-43F1-9F48-D0895353B733Q36462151-3755197D-B4B8-4C48-9CCA-2D5B751D7BEAQ36547354-14889129-3CE0-4EB6-AFC7-5172FA4D60ACQ36811255-6F7EE240-B8F2-47B2-8253-4BEC044F9723Q37293591-811A97C4-1F5A-43FB-A1AA-71DCB5AB50FBQ37405479-83C644D4-834B-43B7-8C84-44FF0B84988EQ37418111-8454D2CC-EB9D-4AA0-888E-9B9C4DF36B14
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
ricercatore
@it
հետազոտող
@hy
name
Mark H Wilcox
@cy
Mark H Wilcox
@en-gb
Mark H. Wilcox
@en
Mark H. Wilcox
@es
Mark H. Wilcox
@nl
Mark H. Wilcox
@sl
type
label
Mark H Wilcox
@cy
Mark H Wilcox
@en-gb
Mark H. Wilcox
@en
Mark H. Wilcox
@es
Mark H. Wilcox
@nl
Mark H. Wilcox
@sl
altLabel
Mark Wilcox
@cy
Mark Wilcox
@en
Mark Wilcox
@en-gb
prefLabel
Mark H Wilcox
@cy
Mark H Wilcox
@en-gb
Mark H. Wilcox
@en
Mark H. Wilcox
@es
Mark H. Wilcox
@nl
Mark H. Wilcox
@sl
P1006
P214
P1006
P106
P1153
55446626100
P2031
1985-01-01T00:00:00Z
P21
P214
P31
P496
0000-0002-4565-2868
P734
P735
P7859
viaf-306217559